Is Wall Street High Or Low On X4 Pharmaceuticals Inc. (XFOR)?


X4 Pharmaceuticals Inc. (NASDAQ:XFOR) traded with an addition of $0.06 to close at $0.91 on Thursday, an upside of 6.82 percent. An average of 1,107,602 shares of common stock have been traded in the last five days. There was a gain of $0.1099 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 2,375,785 shares traded, while the 50-day average volume stands at 1,333,234.

XFOR stock has decreased by -51.83% in the last month. The company shares reached their 1-month lowest point of $0.6500 on 12/19/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $0.65 and a high of $2.63 in 52 weeks. It has reached a new high 2 times so far this year and lost -62.98% or -$1.3840 in price. In spite of this, the price is down -65.57% from the 52-week high.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Insider Transactions

XFOR stock investors should be aware that X4 Pharmaceuticals Inc. (XFOR) stock had its last reported insider trading activity 209 days ago on Jun 03.

Valuation Metrics

X4 Pharmaceuticals Inc. (XFOR) stock’s beta is 0.52. Other valuation ratios to consider include the price-to-book (PB) ratio at 1.15.

Financial Health

The quick ratio of X4 Pharmaceuticals Inc. for the three months ended September 29 was 3.00, and the current ratio was 3.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.30 and a total debt to equity ratio of 0.54 for the quarter ending September 29. Its gross profit as reported stood at $85.11 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, X4 Pharmaceuticals Inc.’s return on assets was -100.40%.

Earnings Surprise

In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$21.87 million in the quarter, while revenues of -$21.21 million were grew 7.73%. The analyst consensus anticipated X4 Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.3 per share, but it turned out to be -$0.26, a 13.30% surprise. For the quarter, EBITDA amounted to -$20.03 million. Shareholders own equity worth $69.23 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at X4 Pharmaceuticals Inc. (XFOR) price momentum. RSI 9-day as of the close on 28 December was 45.28%, suggesting the stock is Neutral, with historical volatility in this time frame at 126.81%.

As of today, XFOR’s price is $0.8459 +13.80% or $0.1099 from its 5-day moving average. XFOR is currently trading -39.60% lower than its 20-day SMA and -22.56% lower than its 100-day SMA. However, the stock’s current price level is -50.22% below the SMA50 and -54.01% below the SMA200.

The stochastic %K and %D were 49.68% and 39.20%, respectively, and the average true range (ATR) was 0.1075. With the 14-day stochastic at 75.27% and the average true range at 0.1186, the RSI (14) stands at 39.16%. The stock has reached 0.0341 on the 9-day MACD Oscillator while the 14-day reading was at 0.0162.

Analyst Ratings

Cantor Fitzgerald launched coverage on X4 Pharmaceuticals Inc. (NASDAQ: XFOR) in its analyst report released on December 22, 2022. The firm assigned the stock an Overweight rating. The consensus rating for X4 Pharmaceuticals Inc. (XFOR) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell XFOR, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 8 others rate it as a “buy”.

What is XFOR’s price target for the next 12 months?

Analysts predict a range of price targets between $3.00 and $7.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for X4 Pharmaceuticals Inc. (XFOR) stock is $4.79.


Please enter your comment!
Please enter your name here